AxoGen (AXGN) CEO On Positive Topline Results For Avance Nerve Graft Product

<p>AxoGen (AXGN) stock price today was up over 6%. AxoGen is a developer and marketer of surgical solutions for peripheral nerve injuries. Recently, AxoGen announced positive topline results for Avance Nerve Graft product. Chairman and CEO Karen Zaderej weighs in on nerve grafting and the recent AxoGen earnings report that indicated $31M in revenue. How will this healthcare stock perform moving forward? </p><p><br></p>